サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1576967

脱毛症の世界市場の評価：タイプ別、性別、治療別、販売別、流通チャネル別、地域別、機会、予測（2017年～2031年）

Alopecia Market Assessment, By Type, By Gender, By Treatment, By Sales, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 235 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
脱毛症の世界市場の評価：タイプ別、性別、治療別、販売別、流通チャネル別、地域別、機会、予測（2017年～2031年）
出版日: 2024年10月25日
発行: Market Xcel - Markets and Data
ページ情報: 英文 235 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の脱毛症の市場規模は、2023年の95億2,000万米ドルから2031年に186億2,000万米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで8.75％の成長が見込まれます。市場は、疾病負担の増加、脱毛症周辺の強力な研究環境、脱毛症に対する意識の高まり、医療システムの強化などの影響を受け、より速いペースで成長すると予測されています。

脱毛症は、傷跡を残さない脱毛を引き起こす炎症性自己免疫疾患であり、患者の身体的・心理的幸福に大きな影響を与えます。脱毛の強さは脱毛症のタイプによって異なりますが、有病率では円形脱毛症がもっとも一般的です。市場の促進要因は、老年人口の増加、脱毛症と多嚢胞性卵巣症候群（PCOS）などの関連疾患の有病率の増加、治療に対する認識と需要の高まり、治療の進歩などです。こうした促進要因にもかかわらず、市場は脱毛症治療に伴う副作用などの課題にも直面しており、これが市場の成長を妨げています。さらに、潜在的な薬剤候補から得られた確かな研究結果が、将来的な市場成長をさらに後押ししています。

2024年7月、Dermaliq Therapeutics, Inc.は、男性型脱毛症に対する同社の局所製品候補、DLQ01の臨床試験から統計的に有意なトップラインデータを発表しました。同試験では、DLQ01はベースラインから12.3％標的部位の毛髪数を増加させ、被験者の83％が肯定的な反応を示しました。本試験の評価項目は、6ヵ月後の試験終了時のベースラインからの標的領域の毛髪数、休止期と退行期の比率、皮膚の安全性の変化でした。試験はオーストラリアのメルボルンにあるSinclair Dermatologyで実施されました。

当レポートでは、世界の脱毛症市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の脱毛症市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • タイプ別
    • 性別
    • 治療別
    • 売上別
    • 流通チャネル別
    • 地域別
    • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
  • 市場マップ分析（2023年）
    • タイプ別
    • 性別
    • 治療別
    • 売上別
    • 流通チャネル別
    • 地域別

第5章 北米の脱毛症市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • タイプ別
    • 性別
    • 治療別
    • 売上別
    • 流通チャネル別
    • シェア：国別
  • 各国の市場の評価
    • 米国の脱毛症市場の見通し（2017年～2031年）
    • カナダ
    • メキシコ

第6章 欧州の脱毛症市場の見通し（2017年～2031年）

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • ポーランド

第7章 アジア太平洋の脱毛症市場の見通し（2017年～2031年）

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第8章 南米の脱毛症市場の見通し（2017年～2031年）

  • ブラジル
  • アルゼンチン

第9章 中東・アフリカの脱毛症市場の見通し（2017年～2031年）

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • イスラエル

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

  • 市場促進要因
  • 市場の課題

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

  • 臨床試験
  • 規制当局の承認

第18章 特許情勢

第19章 ケーススタディ

第20章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • Janssen Global Services Inc.
    • Aclaris Therapeutics, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Sun Pharmaceuticals Industries Limited
    • Dr. Reddy's Laboratories Ltd
    • Aurobindo Pharma
    • Viatris Inc.
    • Pfizer, Inc.
    • Eli Lilly and Company

第21章 戦略的推奨

第22章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 3. Global Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 4. Global Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 5. Global Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 6. Global Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7. Global Alopecia Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 10. North America Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 11. North America Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 12. North America Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 13. North America Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 14. North America Alopecia Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 17. United States Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 18. United States Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 19. United States Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 20. United States Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Canada Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 23. Canada Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 24. Canada Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 25. Canada Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 26. Canada Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Mexico Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 29. Mexico Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 30. Mexico Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 31. Mexico Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 32. Mexico Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 35. Europe Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 36. Europe Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 37. Europe Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 38. Europe Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. Europe Alopecia Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 42. Germany Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 43. Germany Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 44. Germany Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 45. Germany Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. France Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 48. France Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 49. France Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 50. France Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 51. France Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Italy Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 54. Italy Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 55. Italy Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 56. Italy Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 57. Italy Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 58. United Kingdom Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 60. United Kingdom Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 61. United Kingdom Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 62. United Kingdom Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 63. United Kingdom Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Russia Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 66. Russia Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 67. Russia Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 68. Russia Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 69. Russia Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 70. Netherlands Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 72. Netherlands Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 73. Netherlands Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 74. Netherlands Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 75. Netherlands Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 76. Spain Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 78. Spain Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 79. Spain Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 80. Spain Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 81. Spain Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 82. Turkey Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 84. Turkey Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 85. Turkey Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 86. Turkey Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 87. Turkey Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Poland Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 90. Poland Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 91. Poland Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 92. Poland Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 93. Poland Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. South America Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 96. South America Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 97. South America Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 98. South America Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 99. South America Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. South America Alopecia Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 103. Brazil Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 104. Brazil Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 105. Brazil Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 106. Brazil Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 107. Argentina Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 109. Argentina Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 110. Argentina Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 111. Argentina Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 112. Argentina Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 113. Asia-Pacific Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 115. Asia-Pacific Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 116. Asia-Pacific Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 117. Asia-Pacific Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 118. Asia-Pacific Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 119. Asia-Pacific Alopecia Market Share (%), By Country, 2017-2031F
  • Figure 120. India Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 122. India Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 123. India Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 124. India Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 125. India Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. China Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 128. China Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 129. China Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 130. China Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 131. China Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. Japan Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 134. Japan Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 135. Japan Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 136. Japan Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 137. Japan Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Australia Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 140. Australia Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 141. Australia Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 142. Australia Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 143. Australia Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 144. Vietnam Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 146. Vietnam Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 147. Vietnam Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 148. Vietnam Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 149. Vietnam Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 150. South Korea Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 152. South Korea Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 153. South Korea Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 154. South Korea Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 155. South Korea Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 156. Indonesia Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 158. Indonesia Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 159. Indonesia Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 160. Indonesia Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 161. Indonesia Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. Philippines Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 164. Philippines Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 165. Philippines Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 166. Philippines Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 167. Philippines Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 168. Middle East & Africa Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 170. Middle East & Africa Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 171. Middle East & Africa Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 172. Middle East & Africa Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 173. Middle East & Africa Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. Middle East & Africa Alopecia Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 177. Saudi Arabia Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 178. Saudi Arabia Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 179. Saudi Arabia Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 180. Saudi Arabia Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. UAE Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 183. UAE Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 184. UAE Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 185. UAE Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 186. UAE Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187. South Africa Alopecia Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Alopecia Market Share (%), By Type, 2017-2031F
  • Figure 189. South Africa Alopecia Market Share (%), By Gender, 2017-2031F
  • Figure 190. South Africa Alopecia Market Share (%), By Treatment, 2017-2031F
  • Figure 191. South Africa Alopecia Market Share (%), By Sales, 2017-2031F
  • Figure 192. South Africa Alopecia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Gender Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Sales Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX12163

Global alopecia market is projected to witness a CAGR of 8.75% during the forecast period 2024-2031, growing from USD 9.52 billion in 2023 to USD 18.62 billion in 2031. The market for alopecia therapeutics is anticipated to thrive at a faster pace under the influence of the growing disease burden, robust research environment around the disease, rising awareness about alopecia, and strengthening the healthcare system.

Alopecia is an inflammatory autoimmune disease that causes nonscarring hair loss that can significantly impact both the physical and psychological well-being of patients. The intensity of hair loss may vary depending on the type of alopecia; alopecia areata is the most common type of alopecia in terms of prevalence. Drivers for this market include the increasing geriatric population, rising prevalence of alopecia and related conditions like Polycystic Ovary Syndrome (PCOS), growing awareness and demand for treatments, and advancements in therapies. Despite these driving forces, the market also faces some challenges, such as side effects associated with alopecia treatment, which hinder market growth. Additionally, robust research findings from potential pharmaceutical candidates further enhance futuristic market growth.

In July 2024, Dermaliq Therapeutics, Inc. announced statistically significant topline data from a clinical trial for its topical product candidate DLQ01 for male pattern baldness. The trial showed that DLQ01 increased target area hair counts by 12.3% from baseline, with 83% of subjects responding positively. Endpoints of the study included the changes from baseline at the end of the study at six months in target area hair counts, anagen to telogen ratios, and cutaneous safety. The trial was conducted at Sinclair Dermatology, Melbourne, Australia.

High Disease Burden of Alopecia to Boost Market Demand

The population affected by alopecia conditions is steadily growing, and thus, the demand for alopecia therapeutics is also rising swiftly. The high disease burden of alopecia not only underscores the urgent need for effective treatments but also stimulates market growth through increased prevalence, significant psychosocial impacts on patients, and a robust focus on research and development. These factors collectively enhance the therapeutic landscape for alopecia, promising a dynamic future for the market. The efforts made by stakeholders such as market players, research organizations, and associations to reduce the disease burden are further providing market growth. According to the data published by the National Alopecia Areata Foundation, approximately 2% of people worldwide will experience alopecia areata at some point in their lives. In the United States, nearly 7 million people and around 160 million people globally either have or will develop alopecia areata. Currently, about 700,000 people in the United States have some form of alopecia areata.

Novel Therapy Development to Propel Market Growth

The conventional treatment options for alopecia include pharmaceutical administration through oral and topical routes and platelet-rich plasma therapy. Novel therapies have evolved in recent times which hold promising growth for the market. Researchers across the globe are involved in various research models to explore the therapeutic potential of novel therapies to stimulate hair growth and reverse hair loss. One such example is demonstrated in an article published in Advanced Materials journals in April 2024; researchers have created a new treatment to reverse hair loss caused by the autoimmune disease alopecia areata. They used a microneedle patch to painlessly target affected areas of the skin. Alopecia areata leads to hair loss when T cells mistakenly attack hair follicles. To regain control over hyperactive immune cells, researchers from Brigham and Women's Hospital and MIT delivered T cell regulators directly to the sites of hair loss to stop the autoimmune activity.

Alopecia Areata Segment to Dominate the Alopecia Market

The alopecia areata segment is poised to dominate the global alopecia market due to several key factors. As an autoimmune condition characterized by patchy hair loss, alopecia areata affects approximately a significant amount of the population. The immune response does not permanently damage hair follicles, allowing for potential regrowth, which is a characteristic feature of this type of alopecia. Genetic predisposition plays a significant role in the development of alopecia areata. Individuals with a family history of autoimmune diseases are at a higher risk. Strategic product launches at regular intervals further enhance the market share of the alopecia areata segment; for instance, in June 2023, Pfizer Inc. announced that the United States Food and Drug Administration has approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. It is the first and only treatment approved by the FDA for adolescents (12 years and above) with severe alopecia areata. LITFULO is a kinase inhibitor that inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma family of kinases.

North America Dominates Alopecia Market

North America is anticipated to emerge as the dominant region in the global alopecia market, securing a substantial market share. The region boasts a sophisticated healthcare system that provides seamless diagnosis and treatment of alopecia. Patients have access to a wide range of treatment options, including advanced therapies and personalized medicine. There is heightened awareness among healthcare professionals and the public about alopecia and available treatment options. The relatively high healthcare expenditure per capita in North America facilitates increased spending on alopecia treatment. This allows patients to access a wide range of treatment options, contributing to the region's dominant market position. As the prevalence of alopecia continues to rise and new treatment options emerge coupled with USFDA approvals, North America is poised to maintain its dominance in the coming years. In July 2024, Sun Pharmaceutical Industries Limited received USFDA approval for LEQSELVI (deuruxolitinib) used for treating an autoimmune disorder in adults. LEQSELVI is a new, twice-daily oral Janus Kinase (JAK) inhibitor that disrupts the pathways involved in hair loss.

Future Market Scenario (2024-2031F)

Rising awareness among common people about alopecia is anticipated to drive the global alopecia market in the future. Several organizations across the globe are working in favor of alopecia awareness and advocacy. Some of these organizations include the National Alopecia Areata Foundation, Alopecia UK, Pfizer Inc., Canadian Alopecia Areata Foundation, Scarring Alopecia Foundation, American Hair Loss Association, Australia Alopecia Areata Foundation, and many more.

In 1986, the National Alopecia Areata Foundation declared September Alopecia Awareness Month, and since then, several awareness campaigns, marches, donation drives, and other initiatives to enhance awareness about alopecia and its treatment options are observed every year. Such initiatives from stakeholder organizations are anticipated to improve the diagnosis rate and thus drive the future demand for alopecia treatment.

Key Players Landscape and Outlook

The alopecia market comprises several market players ranging from small-cap to large-cap companies. Although the greater share of the market is covered by giants like Eli Lilly and Company and Sun Pharmaceutical Industries Limited, the smaller players, startups, are mainly invested in targeted therapies and treatment development, including medical devices like laser caps. The trend of acquisitions and collaborative business has been observed in the market in recent times.

For instance, in September 2024, Eli Lilly and Company, in collaboration with EVA Pharma (a subsidiary of Armanious Group), announced an agreement to increase access to baricitinib for an estimated 20,000 individuals across 49 low- to middle-income countries in Africa by 2030. Baricitinib, discovered by Incyte Corporation and licensed to Lilly, is used in the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19. This collaboration is part of the Lilly 30x30 initiative, which aims to enhance access to quality healthcare for 30 million people living in resource-limited settings annually by 2030.

In March 2023, Sun Pharmaceutical Industries Limited completed its acquisition of Concert Pharmaceuticals, Inc. This company is a late-stage clinical biopharmaceutical company developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor for potentially treating adult patients with moderate to severe alopecia areata.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Alopecia Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Alopecia Areata
      • 4.2.1.2. Cicatricial Alopecia
      • 4.2.1.3. Traction Alopecia
      • 4.2.1.4. Alopecia Totalis
      • 4.2.1.5. Androgenetic Alopecia
      • 4.2.1.6. Alopecia Universalis
      • 4.2.1.7. Others
    • 4.2.2. By Gender
      • 4.2.2.1. Male
      • 4.2.2.2. Female
    • 4.2.3. By Treatment
      • 4.2.3.1. Pharmaceuticals
        • 4.2.3.1.1. Topical
          • 4.2.3.1.1.1. Minoxidil
          • 4.2.3.1.1.2. Betamethasone Dipropionate
          • 4.2.3.1.1.3. Fluocinolone Acetonide
          • 4.2.3.1.1.4. Finasteride
          • 4.2.3.1.1.5. Others
        • 4.2.3.1.2. Oral
          • 4.2.3.1.2.1. Minoxidil
          • 4.2.3.1.2.2. Finasteride
          • 4.2.3.1.2.3. Corticosteroids
          • 4.2.3.1.2.4. Others
      • 4.2.3.2. Devices
        • 4.2.3.2.1. Laser Cap
        • 4.2.3.2.2. Laser Comb
        • 4.2.3.2.3. Laser Helmet
      • 4.2.3.3. Platelet-Rich Plasma Therapy
    • 4.2.4. By Sales
      • 4.2.4.1. Prescription
      • 4.2.4.2. Over The Counter
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Homecare Settings
      • 4.2.5.2. Dermatology Clinics
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Type
    • 4.3.2. By Gender
    • 4.3.3. By Treatment
    • 4.3.4. By Sales
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. North America Alopecia Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type
      • 5.2.1.1. Alopecia Areata
      • 5.2.1.2. Cicatricial Alopecia
      • 5.2.1.3. Traction Alopecia
      • 5.2.1.4. Alopecia Totalis
      • 5.2.1.5. Androgenetic Alopecia
      • 5.2.1.6. Alopecia Universalis
      • 5.2.1.7. Others
    • 5.2.2. By Gender
      • 5.2.2.1. Male
      • 5.2.2.2. Female
    • 5.2.3. By Treatment
      • 5.2.3.1. Pharmaceuticals
        • 5.2.3.1.1. Topical
          • 5.2.3.1.1.1. Minoxidil
          • 5.2.3.1.1.2. Betamethasone Dipropionate
          • 5.2.3.1.1.3. Fluocinolone Acetonide
          • 5.2.3.1.1.4. Finasteride
          • 5.2.3.1.1.5. Others
        • 5.2.3.1.2. Oral
          • 5.2.3.1.2.1. Minoxidil
          • 5.2.3.1.2.2. Finasteride
          • 5.2.3.1.2.3. Corticosteroids
          • 5.2.3.1.2.4. Others
      • 5.2.3.2. Devices
        • 5.2.3.2.1. Laser Cap
        • 5.2.3.2.2. Laser Comb
        • 5.2.3.2.3. Laser Helmet
      • 5.2.3.3. Platelet-Rich Plasma Therapy
    • 5.2.4. By Sales
      • 5.2.4.1. Prescription
      • 5.2.4.2. Over The Counter
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Homecare Settings
      • 5.2.5.2. Dermatology Clinics
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Alopecia Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Type
          • 5.3.1.2.1.1. Alopecia Areata
          • 5.3.1.2.1.2. Cicatricial Alopecia
          • 5.3.1.2.1.3. Traction Alopecia
          • 5.3.1.2.1.4. Alopecia Totalis
          • 5.3.1.2.1.5. Androgenetic Alopecia
          • 5.3.1.2.1.6. Alopecia Universalis
          • 5.3.1.2.1.7. Others
        • 5.3.1.2.2. By Gender
          • 5.3.1.2.2.1. Male
          • 5.3.1.2.2.2. Female
        • 5.3.1.2.3. By Treatment
          • 5.3.1.2.3.1. Pharmaceuticals
          • 5.3.1.2.3.1.1. Topical
          • 5.3.1.2.3.1.1.1. Minoxidil
          • 5.3.1.2.3.1.1.2. Betamethasone Dipropionate
          • 5.3.1.2.3.1.1.3. Fluocinolone Acetonide
          • 5.3.1.2.3.1.1.4. Finasteride
          • 5.3.1.2.3.1.1.5. Others
          • 5.3.1.2.3.1.2. Oral
          • 5.3.1.2.3.1.2.1. Minoxidil
          • 5.3.1.2.3.1.2.2. Finasteride
          • 5.3.1.2.3.1.2.3. Corticosteroids
          • 5.3.1.2.3.1.2.4. Others
          • 5.3.1.2.3.2. Devices
          • 5.3.1.2.3.2.1. Laser Cap
          • 5.3.1.2.3.2.2. Laser Comb
          • 5.3.1.2.3.2.3. Laser Helmet
          • 5.3.1.2.3.3. Platelet-Rich Plasma Therapy
        • 5.3.1.2.4. By Sales
          • 5.3.1.2.4.1. Prescription
          • 5.3.1.2.4.2. Over The Counter
        • 5.3.1.2.5. By Distribution Channel
          • 5.3.1.2.5.1. Homecare Settings
          • 5.3.1.2.5.2. Dermatology Clinics
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Alopecia Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Alopecia Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Alopecia Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Alopecia Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Janssen Global Services Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Aclaris Therapeutics, Inc.
    • 20.3.3. Merck & Co., Inc.
    • 20.3.4. GlaxoSmithKline plc
    • 20.3.5. Sun Pharmaceuticals Industries Limited
    • 20.3.6. Dr. Reddy's Laboratories Ltd
    • 20.3.7. Aurobindo Pharma
    • 20.3.8. Viatris Inc.
    • 20.3.9. Pfizer, Inc.
    • 20.3.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer